LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +4 | 666.78M | $798.87B | +6 | −3 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 21.81M | — | $19.75B | 3.2% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.65M | — | $18.70B | 2.2% | n/c | 1 | SEC ↗ ×2 |
| 3 | PRIMECAP Management ✦ | 19.62M | — | $17.76B | 12.9% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 17.01M | — | $15.35B | 1.3% | n/c | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 11.00M | — | $9.96B | 1.5% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ ×9 |
| 7 | Fisher Asset Management ✦ | 4.89M | — | $4.43B | 1.9% | n/c | 1 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 1.61M | — | $1.46B | 1.3% | n/c | 1 | SEC ↗ |
| 9 | Tiger Global Management ✦ | 930.00K | — | $842.00M | 3.9% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 827.68K | — | $749.37M | 1.4% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 532.04K | — | $481.70M | 0.4% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 500.83K | — | $453.45M | 0.5% | n/c | 1 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ ×5 |
| 15 | D. E. Shaw & Co. ✦ | 237.22K | — | $214.78M | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 225.78K | — | $204.42M | 0.5% | n/c | 1 | SEC ↗ |
| 17 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ ×4 |
| 18 | Viking Global Investors ✦ | 144.18K | — | $130.53M | 0.5% | n/c | 1 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 95.74K | — | $86.68M | 0.5% | n/c | 1 | SEC ↗ |
| 20 | Dodge & Cox ✦ | 45.98K | — | $41.63M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | GAMCO Investors ✦ | 35.83K | — | $32.44M | 0.4% | n/c | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 11.95K | — | $10.82M | 0.1% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4,323 holders, 762.84M shares, $674.93B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.50K sh · $7.64M
Officer · 2.00K sh · $2.37M
Officer · 5.00K sh · $5.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology